The Trump administration announces new drug pricing agreements with nine biopharmaceutical and pharmaceutical companies, extending discounts to state Medicaid programs. The president says the deals will set Medicaid prices at the lowest levels available and are tied to his “most favored nation” pricing approach.
Bloomberg and The Hill report the specific firms named in the announcement, describing the companies as mid-sized and including examples such as UCB SA, Bridgebio Pharma, and Sun Pharmaceutical Industries. PBS NewsHour and STAT News similarly describe Trump’s statement that the companies will lower prices for Medicaid beneficiaries by selling their drugs to states at discounted rates under the policy framework. Quartz and the other outlets also note that the new round increases participation in the program, raising the total number of companies involved to 26.
Across the coverage, the main differences are in emphasis: some outlets focus on the administration’s bargaining posture and Trump’s stated goal of “lowest prices,” while others highlight the program’s expansion and the cumulative count of participating companies. All describe the same announcement and the same number of new companies joining the Medicaid pricing deals.
